Scientific Program
7:45-8:30 Gathering and registration
8:30-8:40 Welcome and introductory remarks
Prof. Eli Zuckerman, Chair, Israeli Association for the Study of the Liver
8:40-10:20- Session 1
Chairs: Prof. Eli Zuckerman, Dr. Yaakov Maor
8:40-9:05 Epidemiology of NAFLD and burden of the disease
Prof. Valerio Nobili, Italy
9:05-9:30 Mechanism of Injury in NASH and targets for therapy
Prof. Fabio Marra, Florence, Italy
9:30-9:55 Pediatric NAFLD: natural history
Prof. Valerio Nobili, Rome, Italy
9:55-10:20 Gut-liver axis in NASH pathogenesis and clinical implications
Prof. Fabio Marra, Florence, Italy
10:20-10:40 Coffee break and visit at the exhibition
10:40-12:25 Session 2
Chairs: Dr. Matthias Karlebach, Dr. Ohad Etzion
10:40-11:05 Cardio-metabolic morbidity and mortality in NAFLD: pathophysiological mechanisms and implications
Prof. Sven Francque, Belgium
11:10-11:30 HCC in non-cirrhotic patients with NAFLD- who should undergo
surveillance? (Cirrhotic and selective non-cirrhotic populations?)
Prof. Ziv Ben-Ari, Israel
11:35-12:00 Non-invasive assessment of NAFLD – optimizing screening for advanced fibrosis Prof. Sven Francque, Belgium
12:00-12:15 Cost-effectiveness of screening in NAFLD
Prof. Moshe Leshno, Israel
12:15-12:25 Patients' perspective
Hulio Borman, Israel
12:25-13:15 Lunch break and visit at the exhibition
13:00-14:20: Session 3
Chairs: Dr. Tarek Saadi, Dr, Amir Shlomai
13:00-13:25 Lifestyle modification as treatment for NAFLD
Prof. Shira Zelber-Sagi, Israel
13:25-13:50 Metabolic surgery and metabolic endoscopy
Dr. Sigal Fishman, Israel
13:50-14:20 State-of- the-art: New Therapies for NAFLD: 2019 and beyond
Prof. Philip Newsome, UK
14:20-15:15: Session 4
Chairs: Dr. Alice Hershkovitz, Prof. Assy Nimer
14:25-15:15 Case presentation and Round-table discussion (screening, assessment, management, transplantation for NASH)
Moderator: Prof. Oren Shibolet, Israel
Participants: Prof. Philip Newsome, Prof. Valerio Nobili, Prof. Fabio Marra, Prof. Sven Francque, Dr. Sigal Fishman ,Prof. Ziv Ben-Ari, Prof. Eli Zuckerman
15:15 Closing remarks.